$4.75
-5.75%
N/A-$0.29
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its ...
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its ...
OmniAb, Inc. operates within the biotechnology sector, focusing on pioneering therapeutic antibody discovery. The company's core offering is a comprehensive platform that enables pharmaceutical and biotech partners to access a broad spectrum of antibody repertoires and employ sophisticated screening techniques. This facilitates the development of next-generation treatments. Central to OmniAb's technology are proprietary genetically engineered animals, including OmniRat, OmniChicken, and OmniMouse, which are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, the company offers specialized technologies such as OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) for bispecific antibody applications via a common light chain method, and OmniTaur, which leverages the unique structural properties of cow antibodies for challenging targets. Founded in 2012 and headquartered in Emeryville, California, OmniAb was spun off from Ligand Pharmaceuticals in November 2022. As of the latest data, the company has approximately 114 full-time employees. Financially, OmniAb generates revenue through licensing its discovery technology to partners, with a gross profit margin of about 50.5% and a revenue per share of $0.298. The company invests heavily in research and development, with R&D expenses amounting to 113.1% of revenue, reflecting its innovative focus. Key executives include CEO Matthew W. Foehr, who brings over 25 years of pharmaceutical industry experience. OmniAb's platform has contributed to over 280 programs and three product approvals, and the company continues to expand its partnerships, entering into six new license agreements in the second quarter of 2025. The company's strategic vision is to address the growing discovery needs of the global pharmaceutical industry with an efficient, customizable, end-to-end solution, positioning itself as a leader in antibody discovery.